Patients who have this type of muscular toxicity mostly have either no, or mild, clinical symptoms such as muscular weakness, mild or transient elevations of serum creatinine kinase (CK) level, muscle cramps and myalgia. Electromyograms (EMG) of these patients are normal or show slight changes compatible with myopathy in which muscular biopsies reveal findings similar to toxic or non-specific myopathies. In the second pattern, muscular toxicity occurs with rhabdomyolysis. [3] [4] [5] [6] In this pattern of toxicity, concomitant usage of CsA with lovastatin or colchicine has been described [3] [4] [5] [6] [7] and the interaction of CsA metabolism with these drugs has been suggested as the possible cause of the side-effect. 3, 4, 7 We describe here a patient, who had reversible CsA-related muscular toxicity after allogeneic PBSC transplantation.
A 35-year-old man with Ph+ CML, in chronic phase since July 1996, had allogeneic PBSC transplantation from his HLA-matched brother in January 1997. Short-term MTX and CsA (12.5 mg/kg, daily) were given for GVHD prophylaxis. Whole blood CsA concentrations were determined by enzyme immunoassay (Emit 2000 Cyclosporine Specific Assay, Behring Diagnostics, UK) according to the manufacturer's recommmendations. 10 CsA doses were adjusted to keep the whole blood concentrations between 200 to 400 ng/ml. Ciprofloxacin (1000 mg daily), metronidazole (1500 mg daily), fluconazole (100 mg daily), isoniazid (300 mg daily) and sulfamethoxazole-trimethoprim (two double strength tablets, three times a week) were given as prophylaxis. After administration of CsA, the patient gradually became hypertensive without any renal function impairment. Verapamil (240 mg daily), ramipril (5 mg daily), doxazosin (4 mg daily) and metoprolol (200 mg daily) were administered, but did not control the hypertension. He has also had intractable headaches and tremors. . These changes subsided in 1 week and there were no further seizures. Two weeks after the seizures, basal serum CK concentration that consisted totally of the striated muscle fraction, began to increase without any clinically apparent symptoms (Table 1) . Neither sensory nor motor neurological defects could be found. Serum electrolytes remained within normal limits and magnesium and potassium supplementation did not affect the increase in CK levels. Repeated blood CsA concentrations were within therapeutic limits and all the screenings for autoantibodies (anti-nuclear Ab, Abs against extractable nuclear antigens, anti-mitochondrial Ab and anti-smooth muscle Ab) and for viral infections (HBsAg, anti-HBc, anti-HCV, anti-HIV) were negative. Thyroid hormone test results were also normal. The patient did not permit EMG and muscle biopsy. In the following 10 days, the CK level increased up to 8360 IU/l with a parallel rise in the LDH level (714 IU/l). Only CsA dose was reduced to 7 mg/kg/day, without any other drug or dose modification. Within 10 days, his headache and tremors disappeared and serum enzyme concentrations returned to normal ( Table 1) . The CsA concentration was also found to be decreased to 119 ng/ml. His blood pressure has not completely returned to normal but his anti-hypertensive treatment requirement was later restricted to verapamil. We considered this case to be a dose-dependent CsAinduced muscular toxicity as, without any other treatment modification, only tapering CsA dose led to the disappearance of the manifestations. Except for the seizures that occurred 2 weeks before the signs of muscular toxicity, no other known causes of myopathy could be found. Concomitant administration of CsA with enalapril has also been questioned in the etiology of CsA toxicity as two patients with CsA-related myopathy were reported to be using both enalapril and CsA. 1 As no other data confirmed this observation for any form of angiotensin-converting enzyme inhibitors, we could hardly assume that ramipril contributed to the observed toxicity. We were unable to confirm myopathy by biopsy, but we believe that high-dose CsA usage led to subclinical muscular toxicity with the other common features of CsA side-effects. Although this kind of toxicity has been reported mostly in patients with cardiac or renal transplantation, Volin et al 8 and Papa et al 9 described similar muscular disorders after BMT. As far as we know, our patient appears to be the third case of CsA-related muscular toxicity after allogeneic hematopoietic stem cell transplantation. Since allograft patients are usually under prophylaxis with multi-drug regimens, interaction of CsA with these drugs, as in the case of lovastatin and colchicine, should be kept in mind.
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